Areas of Interest

Medical Nutrition Partnerships

Managing rare metabolic conditions requires strict dietary protocols to prevent serious health complications. However, adherence to these diets can be difficult due to the unpalatable nature of traditional protein substitutes and the social and psychological burden of dietary restrictions. 

For instance, Phenylketonuria (PKU) affects approximately 450,000 people worldwide¹, with symptoms ranging from epilepsy to behavioural problems when left untreated. A survey spanning 24 countries found that just 71% of adult PKU patients in follow-up were managed via diet.

Conditions such as hereditary Tyrosinemia type 1 (HT-1) and Homocystinuria (HCU), though rarer, also present significant cognitive risks, among others, if poorly managed. Nutritional management must be tightly controlled, but patients often face limited variety and high burden of care.


In these conditions:

  • Palatability issues discourage regular intake of protein substitutes
  • Complex regimens make adherence harder in everyday life
  • Psychosocial factors, especially among young adults, increase the risk of dietary neglect

Galen’s commitment to medical nutrition is demonstrated through strategic partnerships and a focus on patient-centric solutions. Our capabilities include:

Product Innovation

Developing and offering a range of palatable, easy-to-use medical nutrition products tailored to patient needs.

Regulatory Support

Assisting partners in navigating complex regulatory compliance to bring products to market efficiently.

Market Access Strategies 

Creating targeted plans so products reach the appropriate patient populations effectively.

We are open to in-licensing opportunities for innovative, late-stage, or market-ready medical nutrition and metabolic medicine products such as:

  • High-dose or prescription-only vitamin and mineral therapies
  • Enzyme replacement treatments for metabolic or digestive disorders
  • Adjunctive therapies that support nutrient absorption or gastrointestinal function
  • Oral formulations designed for patients with specific metabolic needs
  • Diagnostic and monitoring solutions designed to support management of specific metabolic and nutritional needs

We are also open to patient centric opportunities that fall outside of this. Our infrastructure allows us to rapidly onboard and support new products through flexible commercial models and experienced regulatory guidance.

Galen owns a portfolio of specialist medical nutrition products for the dietary management of inherited metabolic disorders. We are actively seeking international partners to out-license these products and expand their availability in new territories.

Our current offerings include:

PKU EASY Microtabs Plus

PKU EASY Microtabs Plus are small, slow release, phenylalanine free amino acid tablets with added vitamins and minerals for the dietary management of PKU. Their coated, slow release matrix supports gradual amino-acid release.

View Product
TYR EASY Tablets

TYR EASY Tablets are for the dietary management of Tyrosinemia (TYR) under strict medical supervision. They are a tyrosine and phenylalanine‑free protein substitute containing essential and non‑essential amino acids.

View Product
HCU EASY Tablets

HCU EASY Tablets are for use in the dietary management of proven HCU under strict medical supervision. They are a methionine-free protein substitute tablet containing essential and non-essential amino acids.

View Product

If you’re developing a product within the medical nutrition and metabolic medicine space and need a partner with the infrastructure, responsiveness, and commercial focus to help it succeed, Galen is ready to collaborate.

References

  1. Hillert, A., Anikster, Y., Belanger-Quintana, A., Burlina, A., Burton, B.K., Carducci, C., et al. (2020) ‘The genetic landscape and epidemiology of phenylketonuria’, American Journal of Human Genetics, 107(2), pp.234–250. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7413859/ (Accessed: 12 October 2026).
  2. Trefz, F.K., van Spronsen, F.J., MacDonald, A., Feillet, F., Muntau, A.C., Belanger-Quintana, A., Burlina, A., Demirkol, M., Giovannini, M. and Gasteyger, C. (2015) ‘Management of adult patients with phenylketonuria: survey results from 24 countries’, European Journal of Pediatrics, 174(5), pp.119-127. Available at: https://ern-ithaca.eu/wp-content/uploads/2020/12/Trefz_PKUadult_EurJPediatr2015.pdf (Accessed: 12 October 2026).

Interested in Partnering with Us?

If you would like to explore how our expertise could add value to your product or for an initial discussion about partnering with us, get in touch today.

Contact Us

Aimee Lappin

Business Development Support Manager

Johnny McGaughey

Vice President of Business Development

Natasha Guy

Business Development Licensing Manager

If you would like to learn more about partnering with Galen, explore career opportunities, or speak with our teams, we invite you to get in touch and continue the conversation.